1. Scrip

In DMD, Summit Falls Well Short Of Peak It Hoped For

 
• By Joseph Haas

Summit’s utrophin modulator, ezutromid, posted intriguing interim data in January, but failed to meet the primary and all secondary endpoints in a Phase II study. The UK firm discontinued development of ezutromid and will now focus on novel antibiotic candidates.

Render illustration of Clinical Trial title on medical documents

The promise of interim data reported in January didn’t hold up, as Summit Therapeutics PLC revealed June 27 that its Phase II Duchenne muscular dystrophy candidate ezutromid failed to meet the primary endpoint and all secondary endpoints in the 40-patient PhaseOut DMD study. The Oxford, UK-based firm said it has discontinued all development of the utrophin modulator and is undertaking cost-reduction measures as it switches focus to novel-mechanism antibiotic development.

Summit CEO Glyn Edwards described the study results as disappointing, but also definitive, in a same-day conference call. The company...

More from Rare Diseases

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.